Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

An 18 Percent Solution? Lilly And Daiichi Bet On A Premium Price For Effient Over Plavix

This article was originally published in The Pink Sheet Daily

Executive Summary

Wall Street analysts fret over a black box warning and see a slow uptake for Effient, but still expect drug to reach blockbuster status.

You may also be interested in...



Lilly Will Play The Metabolism Card In Effient's Imminent U.S. Launch

Meanwhile, second-quarter sales of the oral platelet inhibitor outside the U.S. prove to be…thin.

Lilly Will Play The Metabolism Card In Effient's Imminent U.S. Launch

Meanwhile, second-quarter sales of the oral platelet inhibitor outside the U.S. prove to be…thin.

Effient Approval Shows Mark Of FDA Controls

Postmarketing trials offer opportunity to investigate a possible means to control the bleeding caused by prasugrel, but REMS includes messaging aimed at limited off-label use.

Related Content

Topics

UsernamePublicRestriction

Register

PS069698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel